NB-4746 (Dose TBD)

Preclinical

NB-4746 (Dose TBD) is one of 7 therapeutic programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Amyotrophic Lateral Sclerosis (ALS)Recruiting

Amyotrophic Lateral Sclerosis (ALS)Preclinical

Recruiting

Competition

Competitive Landscape

12 competitors in Amyotrophic Lateral Sclerosis (ALS)

#DrugCompanyPhaseTrials

Rilutek

AAzurity Pharmaceuticals

Phase 2

1 2

VHB937

Novartis

Phase 2

1 3

Cromolyn Sodium

UUniversity of California, San Francisco

Phase 2

1 4

XT-150

XXalud Therapeutics, Inc.

Phase 1

1 5

NUZ-001

MMerit E. Cudkowicz, MD

Preclinical

1 6

NB-4746 (Dose TBD)

NNura Bio

Preclinical

1 7

MTP-101C

UUniversity of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Amyotrophic Lateral Sclerosis (ALS)

NCT07369076

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

Recruiting·NNura Bio·Preclinical·NCT07369076·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NB-4746 (Dose TBD). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for NB-4746 (Dose TBD). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nura Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: NNura Bio

NB-4746 (Dose TBD)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Amyotrophic Lateral Sclerosis (ALS)1 trial

References

Drug Info

Quick Facts

Related News